An immune stimulatory approach to vaccination against coronavirus

Purpose and goal The goal is to develop a unique candidate vaccine against COVID-19 formulated with our lead immunolide ISR50 that has unique immunostimulatory properties as a vaccine adjuvant inducing a protective respiratory tract coronavirus specific IgA response. In the project, we will focus on finding the optimal formulation of the SARS-CoV-2 antigen with the adjuvant, and conduct animal studies and toxicology verification. We will offer a viable alternative for protection against COVID-19. Expected results and effects The main result of the project will be sufficient scientific evidence needed to enter human trials at the project end. As such, a Principal Investigator will be identified, and a Clinical Study Protocol will be developed. Planned approach and implementation The project has been divided into 6 work packages and will be implemented over a course of 18 months. 1. Antigen production Start: 12.2020 End: 05.2022 2. Adjuvant formulation Start: 02.2021 End: 05.2021 3. Animal model Start: 06.2021 End:11.2021 4. Toxicology Start: 10.2021 End:03.2022 5. Preparing clinical protocol Start: 04.2022 End:05.2022 6. Project management and dissemination Start: 12.2020 End: 05.2022